EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal

Sujata Ojha, William Sessions, Yuhang Zhou, Kyaw L Aung

Current Oncology · 22.10.2025 · 32 (11) · 589

DOI: 10.3390/curroncol32110589 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 22.10.2025. Verfasst von Sujata Ojha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Pancreatic Neoplasms, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies due to late diagnosis and limited treatment options. Circulating tumor DNA (ctDNA) is a promising, minimally invasive biomarker that could improve the clinical outcomes of patients with PDAC by enabling early disease detection, minimal residual disease (MRD) assessment, precise prognostication, and accurate treatment monitoring. CtDNA has prognostic as well as predictive value in both resectable and metastatic settings, with serial measurements enhancing risk stratification and recurrence prediction beyond CA19-9. However, despite the promise, the true potential of ctDNA has not yet been fulfilled in patients with PDAC. The current limitations include a low sensitivity of ctDNA assays in early stage PDAC, challenges in the assay interpretation due to the specific nature of ctDNA shedding in PDAC, inter-patient heterogeneity, and technical variability. As precision oncology advances, ctDNA will be a powerful tool for personalized care in PDAC, but rigorous validation of its use within specific clinical contexts is still needed before the true potential of ctDNA is realized for patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAPancreatic NeoplasmsBiomarkers, TumorCarcinoma, Pancreatic DuctalAdenocarcinomaHumansPrognosis

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)liquid biopsyminimal residual disease (MRD)pancreatic ductal adenocarcinoma (PDAC)precision oncology

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Internal Medicine, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA.
  • Division of Hematology and Oncology, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA.

Förderung

  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Ojha, S., Sessions, W., Zhou, Y., & Aung, K. L. (2025). ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal. Current Oncology, 32(11), 589. https://doi.org/10.3390/curroncol32110589

Vancouver

Ojha S, Sessions W, Zhou Y, Aung KL. ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal. Current Oncology. 2025;32(11):589. doi:10.3390/curroncol32110589

BibTeX
@article{Ojha2025,
  author = {Ojha, Sujata and Sessions, William and Zhou, Yuhang and Aung, Kyaw L},
  title = {ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {11},
  pages = {589},
  doi = {10.3390/curroncol32110589}
}
Kostenlos starten →